A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biotechnology company focused on applying our industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. We have created a comprehensive set of platform technologies to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. We seek to apply our ability to engineer macrophages and monocytes, either in vivo or ex vivo, using approaches and delivery systems most appropriate to each specific indication, to meaningfully alter the course of the disease. Our proprietary CAR-M platform uses chimeric antigen receptors, or CARs, to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted anti-tumor immunity.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 53M | - | - | 40M | 27M | - |
| Net Income | 8.0M | -60M | -87M | - | -336K | -23M |
| EPS | $0.19 | $-1.46 | $-2.59 | $-575.40 | $0.00 | $-3.80 |
| Free Cash Flow | -22M | -60M | -82M | 20M | -69M | -31M |
| ROIC | 125.9% | -161.3% | -99.1% | - | -0.2% | -17.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.09 | 0.12 | -0.24 | 0.40 | -14.31 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 11M | -62M | -89M | -56M | -8.5M | -21M |
| Operating Margin | 20.6% | - | - | -140.4% | -32.2% | - |
| ROE | 0.0% | - | -327.4% | - | -0.2% | - |
| Shares Outstanding | 42M | 41M | 34M | 0M | 10M | 6M |
Carisma Therapeutics Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is -9.5%.
Carisma Therapeutics Inc. (CARM) has a 5-year average return on invested capital (ROIC) of -69.4%. This is below average and may indicate limited pricing power.
Carisma Therapeutics Inc. (CARM) has a market capitalization of $1M. It is classified as a small-cap stock.
Carisma Therapeutics Inc. (CARM) does not currently pay a regular dividend.
Carisma Therapeutics Inc. (CARM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Carisma Therapeutics Inc. (CARM) generated $-60 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Carisma Therapeutics Inc. (CARM) reported earnings per share (EPS) of $-1.46 in its most recent fiscal year.
The Ledger Terminal provides 12 years of financial data for Carisma Therapeutics Inc. (CARM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Carisma Therapeutics Inc. (CARM) has a book value per share of $-0.67, based on its most recent annual SEC filing.